Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval
Executive Summary
Novartis will conduct holter heart monitoring in Foradil Aerolizer patients as a Phase IV commitment following the approval of formoterol for chronic obstructive pulmonary disease Sept. 25.